BPMC
CRSP icon

Buckland Partners Management Co’s CRISPR Therapeutics CRSP Stock Holding History

Buckland Partners Management Co’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$218K Buy
+4,000
New +$211K 0.11% 93
2026
Q1 		– Sell
-4,000
Closed -$210K – 94
2025
Q4 		$210K Buy
+4,000
New +$240K 0.12% 100

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Buckland Partners Management Co's CRSP Position: Q2 2026 in Review

Buckland Partners Management Co opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 4,000 shares worth $218K. The stake represents 0.11% of the portfolio and ranks #93 among its holdings. This is a return to the name: Buckland Partners Management Co previously reported a position in CRSP as recently as Q4 2025.

Buckland Partners Management Co first reported a position in CRSP in Q4 2025 and has held it in 2 quarters since. 522 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Buckland Partners Management Co held 4,000 shares of CRISPR Therapeutics worth $218K as of Q2 2026.
  • CRISPR Therapeutics was a new Buckland Partners Management Co position in Q2 2026.
  • CRISPR Therapeutics made up 0.11% of Buckland Partners Management Co's portfolio in Q2 2026, its #93 holding.
  • Buckland Partners Management Co first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 522 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Buckland Partners Management Co's 13F filing for Q2 2026, filed 7 Aug 2026.